产品说明书
Valpromide
 |
同义名 : | 2-丙基戊酰胺 ;Depamide;Dipropylacetamide;2-propylpentanamide |
| CAS号 : | 2430-27-5 | |
| 货号 : | A689252 | |
| 分子式 : | C8H17NO | |
| 纯度 : | 97% | |
| 分子量 : | 143.227 | |
| MDL号 : | MFCD00051534 | |
| 存储条件： |
粉末 Sealed in dry,Room Temperature 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 50 mg/mL(349.1 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Valpromide (VPM), an amide derivative of valproic acid that is not an HDAC (histone deacetylase) inhibitor, prevented expression of two EBV genes, BZLF1 and BRLF1, that mediate lytic reactivation. VPM also inhibited expression of a viral late gene, but not early genes, when BZLF1 was exogenously expressed. VPM selectively inhibits both viral and cellular gene expression[1]. Valpromide does not induce histone acetylation, does not induce demethylation or expression of CMV-GFP[2]. VPD (Valpromide) had little effect on limb morphology and no significant effect on HDAC activity or the expression of marker genes[3]. While both VPA (valproic acid) and sodium butyrate are reported to block sodium channel function as well as HDACs, regeneration was not inhibited by valpromide, an analogue of VPA that lacks HDAC inhibition but retains sodium channel blocking activity[4]. The HDAC inhibitor trichostatin A (TSA) also inhibited adipogenesis, whereas the VPA analog valpromide, which does not possess HDAC inhibitory effects, did not prevent adipogenesis[5]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
6.98mL 1.40mL 0.70mL |
34.91mL 6.98mL 3.49mL |
69.82mL 13.96mL 6.98mL |
| 参考文献 |
|---|